Summary of IBa inhibition by baclofen, GABA, or α-conotoxins in the presence or absence of GABABRs in HEK cells stably expressing human Cav2.1 or Cav2.3c channels
| Agonist | IBa inhibition (%) | |||
| Cav2.1 and GABABR | Cav2.1 alone | Cav2.3c and GABABR | Cav2.3c alone | |
| Baclofen (50 µM) | 39.9 ± 2.6 (17) | 0 (5) | 39.5 ± 4.3 (11) | 0 (6) |
| GABA (50 µM) | 38.4 ± 2.7 (7) | ND | 39.3 ± 4.1 (9) | ND |
| Vc1.1 (200 nM) | 0 (9) | ND | 25.5 ± 4.2 (9) | ND |
| c-Vc1.1 (200 nM) | 0 (10) | 0 (6) | 34.8 ± 2.9 (16) | 0 (5) |
| PeIA (200 nM) | 0 (3) | ND | 27.0 ± 3.0 (3) | ND |
| Agonist | IBa inhibition (%) | |||
| Cav2.1 and GABABR | Cav2.1 alone | Cav2.3c and GABABR | Cav2.3c alone | |
| Baclofen (50 µM) | 39.9 ± 2.6 (17) | 0 (5) | 39.5 ± 4.3 (11) | 0 (6) |
| GABA (50 µM) | 38.4 ± 2.7 (7) | ND | 39.3 ± 4.1 (9) | ND |
| Vc1.1 (200 nM) | 0 (9) | ND | 25.5 ± 4.2 (9) | ND |
| c-Vc1.1 (200 nM) | 0 (10) | 0 (6) | 34.8 ± 2.9 (16) | 0 (5) |
| PeIA (200 nM) | 0 (3) | ND | 27.0 ± 3.0 (3) | ND |
Values represent mean ± SEM; n, number of experiments in parentheses; ND, not determined.